Innate immunity in Alzheimer's disease: the relevance of animal models?

J Neural Transm (Vienna) · 2018 · PMC5911273 · PMID 28516241

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, analysis of the solanezumab data in people with mild AD showed a trend toward improved cognition moving the field of immunotherapy in AD from established AD towards the prodromal or mild AD with the aim to halt the cognitive decline as early as possible.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.